Barinthus Biotherapeutics (NASDAQ:BRNS) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Barinthus Biotherapeutics (NASDAQ:BRNS) to a hold rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Separately, Weiss Ratings upgraded shares of Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $4.00.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock opened at $0.73 on Wednesday. The firm has a market capitalization of $29.87 million, a PE ratio of -0.71 and a beta of -0.39. Barinthus Biotherapeutics has a one year low of $0.51 and a one year high of $1.83. The stock’s 50 day moving average price is $0.62 and its 200 day moving average price is $0.63.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. On average, analysts forecast that Barinthus Biotherapeutics will post -0.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC raised its position in shares of Barinthus Biotherapeutics by 115.8% during the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after purchasing an additional 76,800 shares during the period. Rangeley Capital LLC lifted its stake in Barinthus Biotherapeutics by 88.8% in the first quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after buying an additional 75,024 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its holdings in shares of Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after acquiring an additional 100,000 shares during the period. 25.20% of the stock is owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.